Form 4: Guardant Health Executive Reports Stock Transactions

Guardant Health, Inc. executive Kumud Kalia reported transactions involving the acquisition of common stock and restricted stock units.

Summary

• Kumud Kalia, Chief Information Officer at Guardant Health, Inc., reported several transactions on July 1, 2026.
• These transactions include the acquisition of common stock through the vesting of restricted stock units (RSUs).
• A total of 1,607 shares were acquired under an RSU award granted on November 7, 2022, with 25% vesting on October 1, 2023, and the remainder vesting quarterly.
• Additionally, 1,084 shares were acquired under an RSU award granted on December 13, 2023, with 33% vesting on October 1, 2024, and the remainder vesting quarterly.
• Further acquisitions include 1,994 shares from an RSU award granted on November 8, 2024, vesting quarterly, and 1,361 shares from an RSU award granted on March 12, 2025, vesting quarterly.
• A separate transaction involved the retention of 3,066 shares by the company to cover tax withholding obligations upon the vesting of an RSU installment, valued at $170.77 per share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it solely reports routine executive stock transactions and does not provide insights into the company's financial health or strategic direction.

Positives

• Vesting of restricted stock units indicates continued equity-based compensation for the executive, aligning their interests with the company.
• The acquisition of shares through RSU vesting demonstrates progress in the company's long-term incentive plans.
• The retention of shares for tax withholding is a standard procedure that ensures compliance without immediate cash outflow for the executive.

Negatives

• The filing does not detail the company's financial performance or strategic updates, focusing solely on executive stock transactions.
• The value of the retained shares for tax withholding ($170.77) might be lower than the current market price, though this is not explicitly stated as a negative.

Risks

• The retention of shares for tax withholding obligations could imply that the executive may not have sufficient cash to cover these taxes, though this is a common practice.
• The vesting schedules of RSUs are subject to continued employment, meaning any departure before vesting would result in forfeiture of unvested awards.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's financial performance or future operations.

Management Comments

• The filing includes a signature by 'John G. Saia, as attorney-in-fact for Kumud Kalia', indicating delegation for the filing.
• Explanations detail the vesting schedules and conditions for various restricted stock unit awards.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions in the biotechnology and diagnostics sector, providing transparency on executive compensation and potential insider trading activity. Guardant Health operates in the precision oncology market, where executive compensation often includes significant equity components.

Stakeholder Impact

• Shareholders: Gain insight into executive compensation and potential insider activity, though this filing does not indicate buying or selling for personal profit.
• Employees: The vesting of RSUs reinforces the company's strategy of using equity to incentivize and retain employees.
• Management: Confirms the ongoing compensation structure for key executives.

Next Steps

• Continued vesting of restricted stock units according to the outlined schedules.
• Potential future transactions by the reporting person, which will be subject to further SEC filings if they meet reporting thresholds.

Key Dates

Keywords

Guardant Health, GH, Form 4, SEC Filing, Insider Trading, Stock Options, Restricted Stock Units, Executive Compensation, Kumud Kalia, Chief Information Officer, Beneficial Ownership